Brandon Capital and Jeito Capital, two investors, led a €50m Series C round in CatalYm, a biotechnology company, with participation from Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. “The success of our Series C financing, based on strong clinical data, is a further validation that visugromab is emerging as a new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape. We deeply value the commitment of our new and existing investors, which will enable further clinical development, moving our lead program towards pivotal studies," Phil L’Huillier, CatalYm CEO.